Cardioprotection by early metoprolol- attenuation of ischemic vs. reperfusion injury?

There is still a need for adjunct cardioprotection on top of timely reperfusion since mortality and morbidity, notably from heart failure, in patients with acute myocardial infarction remain high [11, 12]. There are plenty preclinical studies reporting mechanical and/or pharmacological strategies to reduce myocardial ischemia/reperfusion injury [6, 17]. However, the translation from preclinical and clinical proof-of-concept studies into better clinical outcome for patients with acute myocardial infarction has been disappointing so far [9, 13]. Among the pharmacological strategies, the beta-blocker metoprolol when given after 15 min of a total of 90 min coronary occlusion reduced infarct size and improved left ventricular functional recovery in pigs [15]. Also, in a proof-of-concept study in patients with acute ST segment elevation myocardial infarction (The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial) metoprolol when given as early as possible i.e. in the ambulance -, reduced infarct size [14]. However, the subsequent phase III trial (the Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention (EARLY-BAMI) trial) did not confirm the prior study and was neutral for infarct size and left ventricular function [20]. In retrospect, it turned out that the dose of metoprolol was lower and the start of treatment later in EARLY-BAMI than METOCARD-CNIC [5]. The importance of early treatment was now systematically addressed in an experimental study by Ibanez and collaborators [19].

In a closed-chest anesthetized pig model the distal left anterior descending coronary artery was occluded with an intracoronary balloon for varying durations from 20 to 60 min with subsequent reperfusion. Intravenous metoprolol (0.75 mg/kg) was given at 20 min coronary occlusion. Effects on ventricular fibrillation, infarct size, coronary microvascular obstruction and left ventricular function (by magnetic resonance imaging) were assessed at days 7 and 45. Metoprolol reduced ventricular fibrillation and improved survival. Metoprolol had no effect on infarct size with coronary occlusion of short duration (20 and 25 min). On the other extreme, with 60 min coronary occlusion, infarct size occupied almost the entire area at risk (determined by contrast multidetector computed tomography), and metoprolol also had no effect. However, in the time window from 30 to 50 min coronary occlusion, metoprolol significantly reduced infarct size. This infarct size reduction was equivalent in magnitude to a delay in infarct progression of about 15 min. Metoprolol reduced coronary microvascular obstruction, which was surprisingly small, and this effect was only significant with 45 min coronary occlusion. Also, metoprolol improved LV ejection fraction at 45 days reperfusion. The entire study was done on a background of amiodarone during ischemia, clopidogrel at reperfusion and oral metoprolol during reperfusion, reflecting a clinically relevant scenario. The study used state-of-the-art methodology [1, 18] and addresses both, a clinically and a conceptually important issue.

From a pragmatic point of view, the clinical message is very clear: metoprolol must be given as early as possible to reduce infarct size, and the present experimental study therefore somewhat reconciles the METOCARD-CNIC and EARLY-BAMI trials.

The conceptual issue, however is more difficult. At first glance, the authors` data support the notion that metoprolol delays ischemic damage rather than reduces reperfusion injury [21]. Indeed, with the unequivocal recognition of irreversible reperfusion injury, the existence of which had been debated for a long time, focus has been largely on the reduction of reperfusion injury, and ischemic injury tended to be neglected [7]. However, there currently exists no method which permits the reliable quantification of ischemic injury without reperfusion [1]. A recent study on remote ischemic perconditioning in pigs reported attenuated ST-segment elevation during ongoing coronary occlusion, thus supporting the idea of a reduction in ischemic rather than reperfusion injury, but a reduction of infarct size could also be ascertained only after subsequent reperfusion [16].

Therefore, there is an alternative interpretation of the present data. The extent of reperfusion injury depends on the duration of the preceding ischemia: with ischemia of short duration, there is also little reperfusion injury. With ischemia of long duration, there is little myocardium left which can be salvaged by reperfusion but also little myocardium that can suffer from reperfusion injury. Thus, reperfusion injury has a maximum at ischemia of intermediate duration [7]. The fact that metoprolol in the present study provided no protection at short duration ischemia (20 and 25 min) and at long duration ischemia (60 min) but did so at intermediate duration of ischemia would fit well to the time course of reperfusion injury which metoprolol could have attenuated. In each case, also metoprolol needed to be on board for more than 10 min to achieve a sufficient tissue concentration.

By definition, coronary microvascular obstruction becomes only manifest with reperfusion [8, 10]. Again, however, it is unclear whether the respective vascular damage is done during ischemia or during reperfusion. Metoprolol reduced coronary microvascular obstruction. In the absence of heart rate reduction, one would have expected a further reduction of coronary flow by beta-blockade [3]. Apparently, however, the attenuation of neutrophil plugging by metoprolol outweighed the vasoconstrictor effects of unmasked alpha-adrenoceptor activation [2].

Currently, it is unclear whether the observed cardioprotective properties of metoprolol can be extrapolated to other beta-blockers. However, the concept of early beta-blockade to salvage ischemic-reperfused myocardium from infarction has been advocated already for timolol more than three decades ago [4].

References

  1. 1.

    Bøtker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di Lisa F, Di Sante M, Efentakis P, Femmino S, Garcia-Dorado D, Giricz Z, Ibanez B, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuhauser M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schluter KD, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G (2018) Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol 113:39. https://doi.org/10.1007/s00395-018-0696-8

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Garcia-Prieto J, Villena-Gutierrez R, Gomez M, Bernardo E, Pun-Garcia A, Garcia-Lunar I, Crainiciuc G, Fernandez-Jimenez R, Sreeramkumar V, Bourio-Martinez R, Garcia-Ruiz JM, Del Valle AS, Sanz-Rosa D, Pizarro G, Fernandez-Ortiz A, Hidalgo A, Fuster V, Ibanez B (2017) Neutrophil stunning by metoprolol reduces infarct size. Nat Commun 8:14780. https://doi.org/10.1038/ncomms14780

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Guth BD, Heusch G, Seitelberger R, Ross J Jr (1987) Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res 60:738–746. https://doi.org/10.1161/01.res.60.5.738

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Hammerman H, Kloner RA, Briggs LL, Braunwald E (1984) Enhancement of salvage of reperfused myocardium by early beta-adrenergic blockade (timolol). J Am Coll Cardiol 3:1438–1443. https://doi.org/10.1016/s0735-1097(84)80282-x

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Hausenloy DJ, Barrabes JA, Bøtker HE, Davidson SM, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes HA, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda R, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado D (2016) Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol 111:70. https://doi.org/10.1007/s00395-016-0588-8

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Hausenloy DJ, Garcia-Dorado D, Bøtker HE, Davidson SM, Downey J, Engel FB, Jennings R, Lecour S, Leor J, Madonna R, Ovize M, Perrino C, Prunier F, Schulz R, Sluijter JP, Van Laake LW, Vinten-Johansen J, Yellon DM, Ytrehus K, Heusch G, Ferdinandy P (2017) Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res 113:564–585. https://doi.org/10.1093/cvr/cvx049

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Heusch G (2015) Treatment of myocardial ischemia/reperfusion injury by ischemic and pharmacological postconditioning. Compr Physiol 5:1123–1145. https://doi.org/10.1002/cphy.c140075

    Article  PubMed  Google Scholar 

  8. 8.

    Heusch G (2016) The coronary circulation as a target of cardioprotection. Circ Res 118:1643–1658. https://doi.org/10.1161/CIRCRESAHA.116.308640

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Heusch G (2017) Critical issues for the translation of cardioprotection. Circ Res 120:1477–1486. https://doi.org/10.1161/CIRCRESAHA.117.310820

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Heusch G (2019) Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res Cardiol 114:45. https://doi.org/10.1007/s00395-019-0756-8

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Heusch G (2020) Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. https://doi.org/10.1038/s41569-020-0403-y,10.1038/s41569-020-0403-y

    Article  PubMed  Google Scholar 

  12. 12.

    Heusch G, Gersh BJ (2017) The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 38:774–784. https://doi.org/10.1093/eurheartj/ehw224

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Heusch G, Rassaf T (2016) Time to give up on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning. Circ Res 119:676–695. https://doi.org/10.1161/CIRCRESAHA.116.308736

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Ibanez B, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos A, Fernandez-Ortiz A, Garcia-Ruiz JM, Garcia-Alvarez A, Iniguez A, Jimenez-Borreguero J, Lopez-Romero P, Fernandez-Jimenez R, Goicolea J, Ruiz-Mateos B, Bastante T, Arias M, Iglesias-Vazquez JA, Rodriguez MD, Escalera N, Acebal C, Cabrera JA, Valenciano J, de Perez PA, Fernandez-Campos MJ, Casado I, Garcia-Rubira JC, Garcia-Prieto J, Sanz-Rosa D, Cuellas C, Hernandez-Antolin R, Albarran A, Fernandez-Vazquez F, Jmdit H, Pocock S, Sanz G, Fuster V (2013) Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. Circulation 128:1495–1503. https://doi.org/10.1161/CIRCULATIONAHA.113.003653

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Ibanez B, Prat-Gonzalez S, Speidl WS, Vilahur G, Pinero A, Cimmino G, Garcia MJ, Fuster V, Sanz J, Badimon JJ (2007) Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation 115:2909–2916. https://doi.org/10.1161/CIRCULATIONAHA.106.679639

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Kleinbongard P, Amanakis G, Skyschally A, Heusch G (2018) Reflection of cardioprotection by remote ischemic perconditioning in attenuated ST-segment elevation during ongoing coronary occlusion in pigs: Evidence for cardioprotection from ischemic injury. Circ Res 122:1102–1108. https://doi.org/10.1161/CIRCRESAHA.118.312784

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Lecour S, Bøtker HE, Condorelli G, Davidson SM, Garcia-Dorado D, Engel FB, Ferdinandy P, Heusch G, Madonna R, Ovize M, Ruiz-Meana M, Schulz R, Sluijter JP, Van Laake LW, Yellon DM, Hausenloy DJ (2014) ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res 104:399–411. https://doi.org/10.1093/cvr/cvu225

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Lindsey ML, Bolli R, Canty JM, Du XJ, Frangogiannis NG, Frantz S, Gourdie RG, Holmes JW, Jones SP, Kloner R, Lefer DJ, Liao R, Murphy E, Ping P, Przyklenk K, Recchia FA, Schwartz Longacre L, Ripplinger CM, Van Eyk JE, Heusch G (2018) Guidelines for experimental models of myocardial ischemia and infarction. Am J Physiol Heart Circ Physiol 314:H812–H838. https://doi.org/10.1152/ajpheart.00335.2017

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Lobo M, Galan-Arriola C, Rossello X, Gonzalez del Hoyo M, Vilchez J, Higuero-Verdejo M, Garcia-Ruiz J, Lopez G, Sanchez-Gonzalez J, Oliver E, Pizarro G, Fuster V, Ibanez B (2020) Metoprolol blunts the time-dependent progression of infarct size. Basic Res Cardiol. https://doi.org/10.1007/s00395-020-0812-4

    Article  PubMed  Google Scholar 

  20. 20.

    Roolvink V, Ibanez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, Dambrink JHE, Escalera N, Lipsic E, Albarran A, Fernández-Ortiz A, Fernández-Avilés F, Goicolea J, Botas J, Remkes W, Hernandez-Jaras V, Kedhi E, Zamorano JL, Navarro F, Alfonso F, García-Lledó A, Alonso J, van Leeuwen M, Nijveldt R, Postma S, Kolkman E, Gosselink M, de Smet B, Rasoul S, Piek JJ, Fuster V, vant Hof AWJ (2016) Early administration of intravenous beta blockers in patients with ST-elevation myocardial infarction before primary PCI. J Am Coll Cardiol 67:2705–2715. https://doi.org/10.1016/j.jacc.2016.03.522

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Rossello X, Ibanez B (2018) Infarct size reduction by targeting ischemic injury: Back to square one. Circ Res 122:1041–1043. https://doi.org/10.1161/CIRCRESAHA.118.312939

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgement

Open Access funding provided by Projekt DEAL. PK was supported by the German Research Foundation (SFB 1116 B8).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Petra Kleinbongard.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kleinbongard, P. Cardioprotection by early metoprolol- attenuation of ischemic vs. reperfusion injury?. Basic Res Cardiol 115, 54 (2020). https://doi.org/10.1007/s00395-020-0814-2

Download citation